Every rare disease is a fragment — split across registries, publications, trials, centres, and a hundred different vocabularies. Navia stitches the fragments into a single, legible view.
Behind every rare diseasea family, asking questions no one has answered.
of rare diseases lack an approved therapy.
A rare neurodegenerative disorder characterised by involuntary choreatic movements, behavioural and psychiatric disturbances, and progressive cognitive decline.
| Trial | Phase | Status |
|---|---|---|
A Pilot Study Assessing… NCT02580793 | Phase 4 | Unknown |
Effect of Tetrabenazine… NCT01834911 | Phase 4 | Completed |
Study of Memantine… NCT00652457 | Phase 4 | Completed |
| Drug | Mechanism | Status |
|---|---|---|
Valbenazine | VMAT2 inhibitor | FDA 2023 |
Deutetrabenazine | VMAT2 inhibitor | FDA 2017 |
Tetrabenazine | VMAT2 inhibitor | FDA 2008 |
Health decisions fail from fragmentation, not absence of data. We link what is already known.
Every record normalised into a disease-first ontology. MeSH, ICD, SNOMED.
Trials, publications, institutions, treatments. Linked, not listed.
Every metric computed from fixed rules. No generative inference.
MEDLINE wired in.
Raw registries to a linked graph. Every step deterministic. Every source traceable.
Primary sources indexed continuously — ClinicalTrials.gov, PubMed, CTIS, FDA/EMA regulatory filings. No manual curation. No secondhand sources.
All records normalised into a shared ontology. Every entity mapped to MeSH, ICD, SNOMED CT, and RxNorm. No proprietary taxonomy.
Normalised records linked across entities into a single relational graph. Trials to institutions, publications to investigators, compounds to indications.
Data sources
Literature
Trial registries
Regulatory & compounds
Identifiers
Capabilities
Every team across the disease lifecycle.
Active trials, approved treatments, and leading centres for any condition — linked, structured, current.
Weeks of literature review compressed into a structured landscape view. Who publishes, where trials run, what gaps remain.
Clearer explanations of your condition and visibility of clinical trials — without needing to be a scientist.
Know the full landscape of your disease area — clinical activity, institutions, trial access — to support your community.
Monitor trial activity, institutional presence, and disease-level research concentration to inform strategy.
Evaluate the competitive landscape before committing resources. Identify concentration and opportunity.
Structured intelligence for rare and complex diseases — biomarkers to pipeline, mapped, linked, and current.
Disease-level intelligence for market assessment, benchmarking, and pipeline evaluation — from data, not narrative.
